Inogen, Inc. (NASDAQ:INGN) Position Increased by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP increased its holdings in Inogen, Inc. (NASDAQ:INGN) by 682.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,346,766 shares of the medical technology company’s stock after acquiring an additional 2,046,766 shares during the quarter. Inogen makes up 2.9% of Divisadero Street Capital Management LP’s portfolio, making the stock its 10th biggest position. Divisadero Street Capital Management LP owned 9.95% of Inogen worth $19,079,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Brown Capital Management LLC grew its holdings in Inogen by 26.6% during the 1st quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock worth $15,941,000 after acquiring an additional 414,903 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Inogen in the second quarter worth about $610,000. Stokes Family Office LLC grew its stake in Inogen by 162.1% in the second quarter. Stokes Family Office LLC now owns 113,985 shares of the medical technology company’s stock worth $927,000 after purchasing an additional 70,500 shares in the last quarter. Vanguard Group Inc. increased its holdings in Inogen by 4.9% in the first quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock valued at $11,492,000 after buying an additional 65,954 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Inogen during the fourth quarter valued at approximately $189,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on INGN shares. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Wednesday, August 7th. StockNews.com raised shares of Inogen from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Inogen Stock Up 0.7 %

Shares of INGN stock opened at $10.75 on Friday. The company has a market cap of $253.45 million, a P/E ratio of -2.59 and a beta of 1.05. The business has a 50 day moving average of $10.94 and a two-hundred day moving average of $8.82. Inogen, Inc. has a 52 week low of $4.13 and a 52 week high of $13.33.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, August 6th. The medical technology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.31. The firm had revenue of $88.77 million during the quarter, compared to the consensus estimate of $82.50 million. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The firm’s revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.42) EPS. Analysts expect that Inogen, Inc. will post -1.92 EPS for the current fiscal year.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.